Next Article in Journal
Two Strategies for the Dosage of Acenocoumarol Co-Administered with Rifampicin in Staphylococcal Prosthetic Valve Endocarditis
Next Article in Special Issue
Mortality of Pandrug-Resistant Klebsiella pneumoniae Bloodstream Infections in Critically Ill Patients: A Retrospective Cohort of 115 Episodes
Previous Article in Journal
Novel Cecropin-4 Derived Peptides against Methicillin-Resistant Staphylococcus aureus
Previous Article in Special Issue
Global Trends in Antimicrobial Use in Food Animals from 2017 to 2030
Brief Report

Fluoroquinolone Can Be an Effective Treatment Option for Acute Pyelonephritis When the Minimum Inhibitory Concentration of Levofloxacin for the Causative Escherichia coli Is ≤16 mg/L

1
Center for Infectious Disease, National Medical Center, Seoul 04564, Korea
2
Department of Internal Medicine, College of Medicine, Hanyang University, Seoul 04763, Korea
3
Division of Infectious Diseases, Department of Internal Medicine, St. Vincent’s Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea
4
Department of Cancer Control and Policy, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang 10408, Korea
5
Department of Internal Medicine, Medical College, Gacheon University, Incheon 21565, Korea
6
Department of Internal Medicine, Ansung Hospital, Gyeonggi Provincial Medical Center, Ansung 17572, Korea
7
Division of Infectious Diseases, Kangdong Sacred Heart Hospital, Hallym University, Seoul 05355, Korea
8
Department of Internal Medicine, School of Medicine, Kyungpook National University, Daegu 41566, Korea
9
Division of Infectious Diseases, Dong-A University Hospital, Dong-A University, Busan 49201, Korea
10
Division of Infectious Diseases, Korea University Guro Hospital, Seoul 08308, Korea
11
Division of Infectious Diseases, Korea University Ansan Hospital, Ansan 15355, Korea
12
Division of Infectious Diseases, Dongsan Hosptial, Keimyeong University, Daegu 41931, Korea
13
Division of Infectious Diseases, Seogwipo Medical Center, Jeju 63585, Korea
*
Author to whom correspondence should be addressed.
Yeonjae Kim and Bongyoung Kim contributed equally to this article as first authors.
Received: 24 November 2020 / Revised: 30 December 2020 / Accepted: 31 December 2020 / Published: 2 January 2021
(This article belongs to the Special Issue Antimicrobial Resistance: The Final Frontier)
The purpose of this study was to determine whether the fluoroquinolone (FQ) minimum inhibitory concentration (MIC) for the causative agent Escherichia coli influences the clinical response of FQ treatment at 72 h in patients with community-acquired acute pyelonephritis (CA-APN). We prospectively collected the clinical data of women with CA-APN from 11 university hospitals from March 2010 to February 2012 as well as E. coli isolates from the urine or blood. In total, 78 patients included in this study received FQ during the initial 72 h, and the causative E. coli was detected. The clinical response at 72 h was significantly higher in patients with a levofloxacin MIC ≤ 16 mg/L than in those with an MIC > 16 mg/L (70.4% vs. 28.6%, p = 0.038). No difference was observed in clinical response at 72 h based on ciprofloxacin MIC. To summarize, FQ can be an effective treatment option for CA-APN when levofloxacin MIC against E. coli is ≤16 mg/L. View Full-Text
Keywords: urinary tract infection; pyelonephritis; E. coli; fluoroquinolone; treatment urinary tract infection; pyelonephritis; E. coli; fluoroquinolone; treatment
Show Figures

Figure 1

MDPI and ACS Style

Kim, Y.; Kim, B.; Wie, S.H.; Kim, J.; Ki, M.; Cho, Y.K.; Lim, S.K.; Lee, J.S.; Kwon, K.T.; Lee, H.; Cheong, H.J.; Park, D.W.; Ryu, S.Y.; Chung, M.H.; Pai, H. Fluoroquinolone Can Be an Effective Treatment Option for Acute Pyelonephritis When the Minimum Inhibitory Concentration of Levofloxacin for the Causative Escherichia coli Is ≤16 mg/L. Antibiotics 2021, 10, 37. https://0-doi-org.brum.beds.ac.uk/10.3390/antibiotics10010037

AMA Style

Kim Y, Kim B, Wie SH, Kim J, Ki M, Cho YK, Lim SK, Lee JS, Kwon KT, Lee H, Cheong HJ, Park DW, Ryu SY, Chung MH, Pai H. Fluoroquinolone Can Be an Effective Treatment Option for Acute Pyelonephritis When the Minimum Inhibitory Concentration of Levofloxacin for the Causative Escherichia coli Is ≤16 mg/L. Antibiotics. 2021; 10(1):37. https://0-doi-org.brum.beds.ac.uk/10.3390/antibiotics10010037

Chicago/Turabian Style

Kim, Yeonjae, Bongyoung Kim, Seong H. Wie, Jieun Kim, Moran Ki, Yong K. Cho, Seung K. Lim, Jin S. Lee, Ki T. Kwon, Hyuck Lee, Hee J. Cheong, Dae W. Park, Seong Y. Ryu, Moon H. Chung, and Hyunjoo Pai. 2021. "Fluoroquinolone Can Be an Effective Treatment Option for Acute Pyelonephritis When the Minimum Inhibitory Concentration of Levofloxacin for the Causative Escherichia coli Is ≤16 mg/L" Antibiotics 10, no. 1: 37. https://0-doi-org.brum.beds.ac.uk/10.3390/antibiotics10010037

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop